Compound 331 selectively induces glioma cell death by upregulating miR-494 and downregulating CDC20

Malignant gliomas are the most common malignant tumors in the central nervous system (CNS). Up to date, the prognosis of glioma is still very poor, effective therapy with less side-effect is very necessary. Herein, we identify a compound named as “331” selectively induced cell death in glioma cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lei, Niu, Tianhui, Huang, Yafei, Zhu, Haichuan, Zhong, Wu, Lin, Jian, Zhang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495416/
https://www.ncbi.nlm.nih.gov/pubmed/26153143
http://dx.doi.org/10.1038/srep12003
Descripción
Sumario:Malignant gliomas are the most common malignant tumors in the central nervous system (CNS). Up to date, the prognosis of glioma is still very poor, effective therapy with less side-effect is very necessary. Herein, we identify a compound named as “331” selectively induced cell death in glioma cells but not in astrocytes. Compound 331 upregulated miR-494 and downregulated CDC20 in glioma cells but not in astrocytes. These results suggest that compound 331 could be a potential drug selectively targeting glioma cells through upregulating miR-494 and downregulating CDC20.

Ejemplares similares